Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Efaproxiral · 3 trials · 4 indications
| Arm | Type | Description |
|---|---|---|
| Efaproxiral + WBRT + Supplemental Oxygen | EXPERIMENTAL | - |
| WBRT + Supplemental Oxygen | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Efaproxiral | DRUG | 75 mg/kg, administered over 30 minutes via a central venous access device (CVAD). Administered 30 minutes prior to the start of whole brain radiation therapy (WBRT) on each WBRT treatment day for 10 days. |
| Whole Brain Radiation Therapy (WBRT) | RADIATION | 3.0 Gy per day for 10 days (30.0 Gy total) of WBRT. |
| Supplemental Oxygen | OTHER | 4 L/minute by nasal cannula. Administered at least 35 minutes prior to WBRT, during WBRT and until 15 minutes after completion of WBRT on all WBRT treatment days. |
| radiation therapy | RADIATION | - |
| carboplatin | DRUG | - |
| chemotherapy | DRUG | - |
| paclitaxel | DRUG | - |
Inclusion Criteria: * Adult women with brain metastases from breast cancer * Minimum KPS of 70 Exclusion Criteria: * Previous treatment for brain metastases, including brain surgery and any form of radiation to the brain
Top 20 of 97 competitors